Satellite Breakfast Symposium The Specialty Pharmacy Review BoardTM - Examining Emerging Therapies and Care Management Interventions for Alzheimer's Disease

Jointly provided by Medical Education Resources, Inc. and Impact Education, LLC.

Supported by independent educational grants from Avanir Pharmaceuticals, Inc. and Lilly USA, LLC. For further information concerning Lilly grant funding visit www.LillyGrantOffice.com.

Wednesday, March 29, 2017 6:00 AM - 8:00 AM Colorado Convention Center Room Mile High 1A-1C Denver, CO

Held in conjunction with AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017.

Don't miss the free CE archive of this activity! Certified for nurses, pharmacists, and physicians. Begin now at www.ImpactEdu.net/Alzheimers You may use the links below to download the slides as well as the screening tools discussed during the symposium. Click here to download the slides from this symposium. St. Louis University Mental Status (SLUMS™) Montreal Cognitive Assessment (MoCA) Mini-Cog™ (MC) Family Questionnaire The Mini-Mental State Examination (MMSE®) may be purchased here.

Review Board Topics Include

Cost components of Alzheimer's Disease Emerging therapies for offsetting drug acquisition costs via specific clinical benefits Current and evolving management interventions and benefit design strategies Utilization management strategies and member benefit schema

REVIEW BOARD FACULTY

	Steven G. Avey, MS, RPh, FAMCP Vice President, Specialty Pharmacy Programs MedImpact Healthcare Systems, Inc.		John Fox, MD, MHA Vice President, Associate Chief Medical Officer Medical Affairs Priority Health
	James Kenney, Jr., RPh, MBA Manager, Specialty and Pharmacy Contracts Harvard Pilgrim Health Care		Marwan Sabbagh, MD, FAAN, CCRI Karsten Solheim Chair for Dementia Professor of Neurology Director of the Alzheimer's and Memory Disorders Division Barrow Neurological Institute

WHO SHOULD ATTEND?

This activity is designed to meet the educational needs of managed care pharmacy directors, clinical pharmacists, quality directors, medical directors, members of AMCP, and other managed health care professionals attending AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017.

STATEMENT OF NEED / PROGRAM OVERVIEW

Alzheimer's disease (AD) represents a significant driver of morbidity and mortality in the US, despite being overshadowed by other predominant conditions for which more effective treatment modalities exist. The incidence and mortality associated with the disease is increasing, indicating a key area of concern for managed care stakeholders. An estimated 5.3 million Americans were living with AD in 2015, and as many as 7.1 million will be diagnosed with the disease by 2025 according to the Alzheimer's Association. By 2050, that number may nearly triple to a projected 13.8 million, barring the development of medical breakthroughs to prevent or cure the disease. Unsurprisingly, this considerable burden of illness associated with AD is also accompanied by extensive direct and indirect costs. This symposium will feature a multidisciplinary faculty panel who will present best practices for implementing collaborative treatment and patient management decisions that lead to optimal outcomes for patients with AD. This approach will enhance the audiences' ability to recommend and implement payer specific techniques to improve the continuity of care related to the impact of AD management strategies on clinical outcomes, value, and economic consequences for the entire health care system. The Specialty Pharmacy Review BoardTM format will be similar to a mock pharmacy and therapeutics committee meeting, featuring an expert panel including a leading neurologist in AD research and practice, a specialty pharmacy director, and managed care medical and pharmacy directors.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to demonstrate improved ability to: Describe various diagnostic tools for AD and evaluate their respective benefits and disadvantages for standardized use among network providers Describe the impact of care coordination in AD in terms of patient quality of life and disease outcomes Implement plan-wide initiatives to better coordinate care for AD among primary and ancillary providers in acute and long-term settings Appraise the novel mechanism of action (MOAs) and clinical benefits of emerging disease-modifying agents for the management of AD Recommend benefit design strategies for emerging biologic and small-molecule AD therapies that encourage appropriate utilization while facilitating patient access and adherence Outline the components and benefits of an effective medication therapy management (MTM) program for AD Characterize the role of specialty pharmacy in supporting appropriate utilization and administration of emerging therapies for AD

AGENDA

Date and Time Wednesday, March 29, 2017 6:00 AM - 8:00 AM Colorado Convention Center Room Mile High 1A-1C Denver, CO

6:00 AM	Breakfast and Registration
6:05 AM	Pre-Activity Learning Assessment and Opening Comments James Kenney, Jr., RPh, MBA
6:10 AM	Assessing the Clinical Benefits and MOAs for Emerging Therapies Marwan Sabbagh, MD, FAAN
6:40 AM	Care Coordination Strategies to Enhance Patient Outcomes Across the Continuum of Disease Management Case Study 1: Diagnosis of a 69-year-old Female Plan Member Presenting with Early Symptoms of AD-related Dementia Case Study 2: Referral and Care Coordination for the Management of Mild AD in a 72-year-old Male Plan Member John Fox, MD, MHA
7:05 AM	Medical and Pharmacy Benefit Design Strategies for Emerging Therapies James Kenney, Jr., RPh, MBA
7:25 AM	Pharmacosurveillance and Patient/Caregiver Counseling Approaches to Minimize Medication Errors and Enhance Appropriate Utilization Steven G. Avey, MS, RPh, FAMCP
7:45 AM	Audience Question and Answer Session Key Takeaways and Closing Comments Post-Activity Assessment
8:00 AM	Adjournment

ACCREDITATION INFORMATION

Physician Continuing Medical Education Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Education Resources, Inc. (MER) and Impact Education, LLC. MER is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Medical Education Resources, Inc. designates this live activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Pharmacist Continuing Education Accreditation Statement

Medical Education Resources, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation Medical Education Resources, Inc. designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - 0816-999-17-079-L01-P Type of Activity: Knowledge

Disclosure of Conflicts of Interest It is the policy of Medical Education Resources, Inc. to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. Americans with Disabilities Act Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Impact Education, LLC, prior to the live event at (215) 619-8812. Fee Information No additional fee is required to attend this CPE/CME activity. Please note: No additional fee is required to attend this CPE/CME activity; however, registration to the AMCP Managed Care & Specialty Pharmacy Annual Meeting 2017 is required. Pre-registration will close at 12:00 pm on March 28, 2017. Walk-in registration will be available at the time of the program. If you have any questions, please call (215) 619-8812 or email info@impactedu.net.